Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Legend Biotech (LEGN) Current Deferred Revenue: 2019-2025

Historic Current Deferred Revenue for Legend Biotech (LEGN) over the last 5 years, with Sep 2025 value amounting to $22.6 million.

  • Legend Biotech's Current Deferred Revenue rose 160.19% to $22.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $22.6 million, marking a year-over-year increase of 160.19%. This contributed to the annual value of $46.9 million for FY2024, which is 11.58% down from last year.
  • According to the latest figures from Q3 2025, Legend Biotech's Current Deferred Revenue is $22.6 million, which was down 31.95% from $33.2 million recorded in Q2 2025.
  • In the past 5 years, Legend Biotech's Current Deferred Revenue registered a high of $252.6 million during Q2 2021, and its lowest value of -$60.6 million during Q4 2021.
  • Moreover, its 3-year median value for Current Deferred Revenue was $36.4 million (2025), whereas its average is $23.1 million.
  • In the last 5 years, Legend Biotech's Current Deferred Revenue skyrocketed by 1,549.33% in 2022 and then plummeted by 138.61% in 2024.
  • Over the past 5 years, Legend Biotech's Current Deferred Revenue (Quarterly) stood at -$60.6 million in 2021, then skyrocketed by 1,549.33% to $245.8 million in 2022, then plummeted by 78.44% to $53.0 million in 2023, then dropped by 11.58% to $46.9 million in 2024, then surged by 160.19% to $22.6 million in 2025.
  • Its Current Deferred Revenue was $22.6 million in Q3 2025, compared to $33.2 million in Q2 2025 and $39.5 million in Q1 2025.